# US 12,571,027 B2 · Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,571,027 B2 - Document ID: US12571027B2 - Status: Granted - Kind: B2 - Application number: 18/829,672 - Filed: 2024-09-10 - Published: 2025-01-02 - Granted: 2026-03-10 - Earliest claimed: 2018-05-25 - Assignees: Regeneron Pharmaceuticals, Inc. - Applicants: Regeneron Pharmaceuticals, Inc. - Inventors: Lorah Perlee; Sara Hamon; Charles Paulding - Web page: https://patentgrep.com/patent/US12571027B2 ## CPC - C12Q 1/6827: for detection of mutation or polymorphism - A61K 39/001135: {Vascular endothelial growth factor [VEGF]} - A61P 27/00: Drugs for disorders of the senses - C07K 16/22: against growth factors {; against growth regulators} - C07K 16/28: against receptors, cell surface antigens or cell surface determinants - C12Q 1/6809: Methods for determination or identification of nucleic acids involving differential detection - C12Q 1/6883: for diseases caused by alterations of genetic material - G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations - G16B 30/00: ICT specially adapted for sequence analysis involving nucleotides or amino acids - G16B 40/20: Supervised data analysis - G16H 20/10: relating to drugs or medications, e.g. for ensuring correct administration to patients - G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems - A61K 2039/505: {comprising antibodies} - C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered - C07K 2317/55: Fab or Fab' - C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism - C12Q 2600/156: Polymorphic or mutational markers - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY - G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA ## Abstract Disclosed herein are methods and compositions for associating a genetic variant with intraretinal fluid. Also disclosed herein are methods and compositions for associating a genetic variant with visual acuity, anatomic outcomes or treatment frequency. ## Claims ### Claim 1 A method of treating a macular degeneration patient with a vascular endothelial growth factor (VEGF) inhibitor, comprising: administering the VEGF inhibitor under a modified dosing frequency after about one year of administering about 2 mg of the VEGF inhibitor to the patient about every 8 weeks, wherein the modified dosing frequency is administering about 2 mg of the VEGF inhibitor to the patient about every 4 to 6 weeks when the patient does not have one or more of the genetic variants rs2056688, rs5962084, rs5962087, rs5915722, and rs5962095; or administering the VEGF inhibitor under a modified dosing frequency after about one year of administering about 2 mg of the VEGF inhibitor to the patient from about every 8 weeks, wherein the modified dosing frequency is administering about 2 mg of the VEGF inhibitor to the patient about every 9 to 12 weeks when the patient has one or more of the genetic variants rs2056688, rs5962084, rs5962087, rs5915722, and rs5962095. ### Claim 2 (depends on 1) The method of claim 1, wherein the genetic variant is rs5962087. ### Claim 3 (depends on 1) The method of claim 1, wherein the genetic variant is rs5962084. ### Claim 4 (depends on 1) The method of claim 1, wherein the genetic variant is rs2056688. ### Claim 5 (depends on 1) The method of claim 1, wherein the genetic variant is rs5915722. ### Claim 6 (depends on 1) The method of claim 1, wherein the genetic variant is rs5962095. ### Claim 7 (depends on 1) The method of claim 1, wherein the VEGF inhibitor is ranibizumab or aflibercept. ### Claim 8 (depends on 1) The method of claim 1, wherein the VEGF inhibitor is aflibercept. ### Claim 9 (depends on 4) The method of claim 4, wherein the VEGF inhibitor is aflibercept. ### Claim 10 (depends on 1) The method of claim 1, wherein the dosing frequency of administering about 2mg of the VEGF inhibitor to the patient having one or more of the genetic variants is modified from about every 8 weeks to about every 9 weeks. ### Claim 11 (depends on 1) The method of claim 1, wherein the dosing frequency of administering about 2mg of the VEGF inhibitor to the patient having one or more of the genetic variants is modified from about every 8 weeks to about every 10 weeks. ### Claim 12 (depends on 1) The method of claim 1, wherein the dosing frequency of administering about 2mg of the VEGF inhibitor to the patient having one or more of the genetic variants is modified from about every 8 weeks to about every 11 weeks. ### Claim 13 (depends on 1) The method of claim 1, wherein the dosing frequency of administering about 2mg of the VEGF inhibitor to the patient having one or more of the genetic variants is modified from about every 8 weeks to about every 12 weeks. ### Claim 14 (depends on 1) The method of claim 1, wherein the dosing frequency of administering about 2mg of the VEGF inhibitor to the patient not having one or more of the genetic variants is modified from about every 8 weeks to about every 4 weeks. ### Claim 15 (depends on 1) The method of claim 1, wherein the dosing frequency of administering about 2mg of the VEGF inhibitor to the patient not having one or more of the genetic variants is modified from about every 8 weeks to about every 5 weeks. ### Claim 16 (depends on 1) The method of claim 1, wherein the dosing frequency of administering about 2mg of the VEGF inhibitor to the patient not having one or more of the genetic variants is modified from about every 8 weeks to about every 6 weeks.